Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens
Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Anticancer research - 35(2015), 1, Seite 379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fujii, Takeo [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1968600647 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1968600647 | ||
| 003 | DE-627 | ||
| 005 | 20230714172752.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1968600647 | ||
| 035 | |a (DE-599)GBVOLC1968600647 | ||
| 035 | |a (PRQ)p838-b1f4d62b7ff617dcb3f531f0ec9deb0fc149785205bf834c9d35665dd20677720 | ||
| 035 | |a (KEY)0105705720150000035000100379differentialimpactoffosaprepitantoninfusionsiteadv | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Fujii, Takeo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen. 267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant. 41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001). Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines. | ||
| 540 | |a Nutzungsrecht: Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. | ||
| 650 | 4 | |a Breast Neoplasms - drug therapy | |
| 650 | 4 | |a Anthracyclines - administration & dosage | |
| 650 | 4 | |a Cisplatin - administration & dosage | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols - adverse effects | |
| 650 | 4 | |a Antiemetics - therapeutic use | |
| 650 | 4 | |a Nausea - drug therapy | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols - therapeutic use | |
| 650 | 4 | |a Lung Neoplasms - drug therapy | |
| 650 | 4 | |a Morpholines - therapeutic use | |
| 650 | 4 | |a Nausea - chemically induced | |
| 650 | 4 | |a Skin Diseases - chemically induced | |
| 700 | 1 | |a Nishimura, Naoki |4 oth | |
| 700 | 1 | |a Urayama, Kevin Y |4 oth | |
| 700 | 1 | |a Kanai, Hisako |4 oth | |
| 700 | 1 | |a Ishimaru, Hiromasa |4 oth | |
| 700 | 1 | |a Kawano, Junko |4 oth | |
| 700 | 1 | |a Takahashi, Osamu |4 oth | |
| 700 | 1 | |a Yamauchi, Hideko |4 oth | |
| 700 | 1 | |a Yamauchi, Teruo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d Kapandriti : International Inst. of Anticancer Research, 1981 |g 35(2015), 1, Seite 379 |w (DE-627)167913441 |w (DE-600)604549-2 |w (DE-576)015902137 |x 0250-7005 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2015 |g number:1 |g pages:379 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25550575 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_2181 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2015 |e 1 |h 379 | ||